Weakness in the haematology business, arising from the phasing of some large orders, largely dominated the otherwise strong Q3 results of Shire. Total product sales more than doubled to $3.3bn, due to the Baxalta contribution, with the legacy Shire pulling off 13% growth but Baxalta’s heritage business declining by 1% on a pro forma basis. All top-line growth numbers are at CER unless specified otherwise. Business-wise, haematology was down 6% (pro forma), genetic diseases up 6%, neuros
07 Nov 2016
Haemophilia fears mask Baxalta integration and strong initial uptake of Xiidra
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Haemophilia fears mask Baxalta integration and strong initial uptake of Xiidra
Shires Income PLC GBP (SHRS:LON) | 222 -1.1 (-0.2%) | Mkt Cap: 92.0m
- Published:
07 Nov 2016 -
Author:
Kamla Singh -
Pages:
3
Weakness in the haematology business, arising from the phasing of some large orders, largely dominated the otherwise strong Q3 results of Shire. Total product sales more than doubled to $3.3bn, due to the Baxalta contribution, with the legacy Shire pulling off 13% growth but Baxalta’s heritage business declining by 1% on a pro forma basis. All top-line growth numbers are at CER unless specified otherwise. Business-wise, haematology was down 6% (pro forma), genetic diseases up 6%, neuros